Business

Infinity completes 5.7m share offering

Adelene Q. Perkins is the chief executive of Infinity.

Bill Greene/Globe Staff/File 2012

Adelene Q. Perkins is the chief executive of Infinity.

Advertisement

Cambridge-based Infinity ­Pharmaceuticals Inc. said that its 5.7 million-share offering priced flat with Wednesday’s close of $26.33, as it seeks to raise funds for research and ­development costs, potential acquisitions and other purposes, Dow Jones reported. Infinity’s shares had climbed to their highest level in a decade on Tuesday after the company ­reported positive results from an early clinical trial of its drug IPI-145 as a treatment for blood cancers.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com